NOT-DA-21-077: Notice of Early Expiration of PAR-21-022, "Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)"

Notice of Early Expiration of PAR-21-022, "Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)"

Notice Number:

NOT-DA-21-077

Key Dates

Release Date:

Related Announcements

PAR-21-022 - Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

This Notice informs the extramural community of a change in expiration date for Funding Opportunity Announcement (FOA) PAR-21-022 , “Multi-Site Studies for System-Level Implementation of Substance Use Prevention and Treatment Services (R01 Clinical Trial Optional)”. The new expiration date for PAR-21-022 will be November 16, 2021. Applicants wishing to conduct system-level implementation research may consider using PAR-19-274, “Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)” or an appropriate Parent R01 announcement.

The following section of the FOA has been modified.

Currently Reads:

Part 1. Overview Information

Key Dates

Expiration Date

November 16, 2023

Revised to Read (changes shown inbold italics):

Part 1. Overview Information

Key Dates

Expiration Date
November 16, 2021

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Lori Ducharme, Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-827-6331
Email: Lori.Ducharme@nih.gov

Laura Kwako, Ph.D.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Telephone: 301-451-8507
Email: Laura.Kwako@nih.gov

Bob Vollinger, Dr.PH
National Cancer Institute (NCI)
Telephone: 240-276-6919
Email: vollingb@mail.nih.gov